|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
|
MechanismHIV p7 inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.
Start Date16 Sep 2019 |
Sponsor / Collaborator- |
/ CompletedNot ApplicableIIT Biologic MateR clinical performance test for ADA and TCZ Efficacy prediction - Biologic MateR clinical performance test for ADA and TCZ Efficacy prediction
Start Date04 Nov 2014 |
Sponsor / Collaborator- |
/ Unknown statusNot Applicable Estudio piloto, doble ciego, aleatorizado, controlado con placebo, de dosis repetida, para la evaluación de la seguridad y la eficacia antiviral de HPH116 en pacientes infectados por VIH-1 que no hayan recibido tratamiento previoA pilot, double-blinded, randomized, placebo-controlled, repeated dose, assessing HPH116 antiviral safety and efficacy in naïve HIV-1 infected patients. - PoC
Start Date05 Sep 2007 |
Sponsor / Collaborator- |
100 Clinical Results associated with HIV p7
100 Translational Medicine associated with HIV p7
0 Patents (Medical) associated with HIV p7
